Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer.
______________
CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review.
Read here:Â https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext